You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Abbott's CFO said he expects mid-single-digit growth from diagnostics in Q1 2018 and mid-to-high single digit growth for the full year.
The company recorded €13.8 billion in revenues in fiscal 2017, including €4.2 billion in diagnostics, €8.2 billion in imaging, and €1.5 billion in advanced therapies.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
Quest's CEO gave an overview of the firm's business and the lab space in general, while GenMark launched a new system this week aimed at smaller labs.
Among the diagnostic firms presenting at the conference on Tuesday were lab giant LabCorp, diversified medical products firm Hologic, and MDx startups, such as Adaptive Biotechnologies.
Several of the top molecular diagnostic firms presented at the JP Morgan Healthcare Conference on Monday discussing product portfolios, FDA clearances, and plans for 2018.
The company attributed the revenue increase to strong sales of its ePlex molecular diagnostics systems.
For its first fiscal quarter, the firm's diagnostics business revenues are expected to drop to $285 million from $325 million in the prior-year quarter.
The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.
The company also expects to report a 31 percent increase in full-year 2017 revenues.